Variable	Variable Smoking controls (n=65)	
		(n=59)
Age (years)	62 ± 7	63 ± 6
Sex (% male)	68	75
BMI	27.0 ± 3.8	26.9 ± 4.2
Packyears	35 ± 22	48 ± 22*
Current smokers (%)	50	49
Educational level (% high education)	54	49
Socio-economic status (% retired)	62	66
Season of assessment		
Winter (%)	30	31
Spring (%)	23	14
Summer (%)	16	17
Autumn (%)	31	38
FEV ₁ (L)	3.04 ± 0.72	$2.46 \pm 0.65^{*}$
FEV ₁ (% pred)	104 ± 15	85 ± 17*
FVC (L)	4.02 ± 0.88	4.03 ± 0.85
FVC (% pred)	110 ± 15	110 ± 15
FEV ₁ /FVC (%)	76 ± 4	61 ± 7*
GOLD stage I/II (n)		39/20
Group A (%)		100
FRC/TLC _p (%)	57 ± 10	69 ± 14*
RV/TLC (%)	36 ± 7	43 ± 7*
IC/TLC (%)	44 ± 7	38 ± 7*
T _L ,co (% pred)	87 ± 13	78 ± 17*
mMRC 0/mMRC 1 (n)	36/27	28/30
QF (% pred)	92 ± 17	98 ± 21
6MWD (m)	609 ± 67	588 ± 86
6MWD (% pred)	92 ± 9	90 ± 11
VO₂peak (mL*min ⁻¹ *kg ⁻¹)	28.2 ± 7.2	25.4 ± 5.1*
VO ₂ peak (% pred)	117 ± 33	107 ± 28*

Table 1. Demographic and functional characteristics of study subjects.

BMI; Body Mass Index, FEV₁; forced expiratory volume in 1 second, FVC; forced vital capacity, Group A (revised GOLD classification); mMRC 0-1, GOLD 1-2 (former GOLD classification) and 0-1 exacerbations per year, FRC; functional residual capacity, TLC_(p); (predicted) total lung capacity, RV; residual volume, TL_{CO}; diffusion capacity of the lung for carbon monoxide, mMRC; modified Medical Research Council (no subject reported mMRC>1), QF; quadriceps force, 6MWD; six-minute walking distance, VO₂ peak; peak oxygen uptake. *p<0.05 COPD versus smoking controls.

Variable	Factor	SEM	Partial R ²	R ²	Ρ
<u>STEPS</u>					
Intercept	-9040	3160			
6MWD	23	6	0.24	0.24	0.0002
gender	-3832	1149	0.11	0.35	0.0016
T _L ,co	591	282	0.04	0.39	0.04
Daylight time	4	2	0.02	0.41	0.12
MVPA					
Intercept	-177	56			
6MWD	0.33	0.09	0.23	0.23	0.0006
Daylight time	0.10	0.04	0.07	0.30	0.02
PAL					
Intercept	0.70	0.19			
6MWD	0.0008	0.0003	0.14	0.14	0.02
gender	-0.17	0.07	0.07	0.21	0.02
T _L ,co	0.04	0.02	0.04	0.25	0.03
Daylight time	0.0003	0.0001	0.05	0.30	0.05

 Table 2. Determinants of physical activity in subjects with COPD (n=59).

6MWD is expressed in meters, gender (0=female, 1=male), T_L ,co in mmol*min⁻¹*kPa and daylight time as minutes of daylight between sunrise and sunset.

FIGURE LEGENDS

Figure 1. Flow chart of the included study subjects, recruited from the Nelson trial.



Figure 2. Daily physical activity in subjects with COPD and smoking controls with (mMRC1) and without (mMRC0) mild symptoms of dyspnea. *p<0.05 mMRC0 versus mMRC1.



Figure 3. Daily physical activity levels (daily steps (A), daily time spent in moderate-tovigorous intense physical activities (MVPA) (B) and daily physical activity level (PAL (C)) and a reduced diffusion capacity of the lung for carbon monoxide (T_L,co) in subjects with and without COPD. T_L,co below or equal to the median (7.7 mmol*min⁻¹*kPa or 88% predicted for smoking controls and 6.9 mmol*min⁻¹*kPa or 80% predicted for COPD) was defined as a reduced T_L,co. *p<0.05 T_L,co ≥ median versus T_L,co < median.



Figure 4. Daily physical activity levels (daily steps (A), daily time spent in moderate-tovigorous intense physical activities (MVPA) (B) and daily physical activity level (PAL (C)) and a reduced six minute walking distance (6MWD) in subjects with and without COPD. 6MWD below or equal to the median (623 m or 93% predicted for smoking controls and 592 m or 90% predicted for COPD) was defined as a reduced 6MWD. *p<0.05 6MWD ≥ median versus 6MWD < median.



Figure 5. Daily physical activity levels (daily steps (A), daily time spent in moderate-tovigorous intense physical activities (MVPA) (B) and daily physical activity level (PAL (C)) and a reduced peak oxygen consumption (peak VO₂) in subjects with and without COPD. Peak VO₂ below or equal to the median (2.23 L*min⁻¹ or 116% predicted for smoking controls and 2.00 L*min⁻¹ or 102% predicted for COPD) was defined as a reduced peak VO₂. *p<0.05 peak VO₂ ≥ median versus peak VO₂ < median.

